Bios: TB Alliance and Optibrium Webinar
Chris joined the TB Alliance in January 2009 as Directory of Chemistry. He received his BS (magna cum laude) in chemistry from Clemson University in 1980, and his MS in organic chemistry at Stanford in 1982.
From 1982 to 1984 Chris was employed by CIBA-Geigy Pharmaceutics, then returned to Stanford in 1984 to earn his Ph.D in Organic Chemistry. Chris then worked in medicinal chemistry research at Pfizer’s Groton and Sandwich labs. His areas of investigation included veterinary and human drug discovery (infectious disease, inflammation, immunology, oncology and neuroscience) as well as applications of automated synthesis technologies for both lead generation and optimization purposes.
Dr. Cooper joined BMS in Princeton in 1998 to launch the Lead Synthesis Group overseeing design, development, and synthesis of novel, drug-like medicinal chemistry arrays. More recently Cooper’s research team at BMS has been directly responsible for the rapid pharmacological assessment of exploratory biological targets of interest, and the advancement of early- and full-phase discovery programs through hit-to-lead, lead optimization, and pre-development candidate selections.
Matt is CEO of Optibrium. He has a Master of Science in computation from the University of Oxford and a Ph.D. in theoretical physics from the University of Cambridge. As Associate Director at Camitro (UK), ArQule Inc. and then Inpharmatica, he led a team developing predictive ADME models and state-of-the-art intuitive decision-support and visualization tools for drug discovery. In January 2006, he became responsible for management of Inpharmatica’s ADME business, including experimental ADME services and the StarDrop software platform. Following acquisition of Inpharmatica, Matt became Senior Director responsible for BioFocus DPI’s ADMET division and in 2009 led a management buyout of the StarDrop business to found Optibrium, which develops software for small molecule design, optimisation and data analysis. Matt has published over 30 peer-reviewed papers and book chapters on computational chemistry, cheminformatics and drug discovery.